Predictive Biosciences Launches Prostate Cancer Test Based on Epigenomics’ DNA Methylation Marker

Lexington, MA -- 01/29/13
Back To Press & Events

Berlin, Germany, Seattle, WA, and Lexington, MA, U.S.A. - Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, and Predictive Biosciences, an innovative developer of molecular diagnostic tests, today announced that Predictive Biosciences of Lexington, MA, has made commercially available a novel tissue-based test for prostate cancer biopsy confirmation utilizing Epigenomics’ proprietary DNA methylation marker GSTP1.

Pierre Cassigneul, Chief Executive Officer of Predictive Biosciences, stated: “We are excited to build upon our existing CertNDx™ commercial franchise in bladder cancer, with the first of several novel tests we plan to commercialize over the next few years which will address the significant unmet diagnostic clinical needs in prostate cancer”.

Additionally, Noel Doheny, Chief Executive Officer of Epigenomics’ US subsidiary, commented: “We are pleased that Predictive Biosciences has successfully moved forward to introduce their assay based on Epigenomics’ intellectual property into the market. This further demonstrates the growing importance of DNA methylation based tests in cancer diagnostics”.

Share On Twitter Linkedin